CFAS is a member of the newly formed European Prevention of Alzheimer’s Disease Consortium (EPAD) which launched in Paris on January 15th, 2015. The start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
EPAD is a collaborative research initiative to improve the chances of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. It is a five year programme which is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical industries and Associations, EFPIA. It will establish a European-wide register of 24,000 participants of which 1,500 will be invited to participate in a trail to test new treatments for prevention of Alzheimer’s dementia.
Further details can be found at http://www.synapse-managers.com/epad/